4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics Inc ownership filing shows State Street Corporation beneficially owns 2,707,875 shares of common stock, representing 5.3% of the class as of 03/31/2026. The filing lists shared voting power of 2,647,452 and shared dispositive power of 2,707,875 held through affiliated investment-adviser entities.
The report identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as relevant subsidiaries or advisory holders. The form is a Schedule 13G disclosure of beneficial ownership and is signed by an authorized officer on behalf of State Street.
4D Molecular Therapeutics, Inc. files a shelf registration to register up to $400.0 million of securities, which includes $200.0 million of unsold securities previously registered and approximately $200.0 million of additional securities.
The prospectus covers multiple classes — common stock, preferred stock, debt securities, warrants and units — to be sold from time to time under a shelf process. The document is a preliminary prospectus dated May 7, 2026 and states that specific offering terms will be provided in prospectus supplements.
4D Molecular Therapeutics reported a larger net loss as it accelerated investment in its late-stage gene therapy pipeline for the three months ended March 31, 2026. Collaboration and license revenue rose to $3.0 million, primarily from its Otsuka partnership, while research and development spending increased to $65.0 million. The company posted a net loss of $68.8 million, compared with $48.0 million a year earlier, and ended the quarter with $457.6 million in cash, cash equivalents and marketable securities. Management believes this cash balance can fund planned operations for at least one year.
4D Molecular Therapeutics reported Q1 2026 results highlighted by advancing its lead eye disease program and maintaining a strong balance sheet. Collaboration and license revenue reached $3.0 million, while research and development expenses rose to $65.0 million as the company executed Phase 3 trials for 4D-150 in wet age-related macular degeneration.
General and administrative expenses were $11.7 million, and net loss was $68.8 million, or $1.01 per share. Cash, cash equivalents and marketable securities totaled $458 million as of March 31, 2026, which the company expects will fund operations into the second half of 2028. The 4FRONT-1 Phase 3 trial completed randomization of 523 patients, with topline data expected in the first half of 2027, and additional PRISM, SPECTRA and DME Phase 3 milestones are planned through 2026–2027.
4D Molecular Therapeutics is asking stockholders to vote at its all-virtual 2026 annual meeting on June 17, 2026. Investors will elect three Class III directors, ratify PricewaterhouseCoopers as auditor for 2026, and cast a non-binding advisory vote on executive pay. Holders of 52,274,735 common shares as of April 20, 2026 may vote, with additional context of 16,935,665 shares issuable upon exercise of pre-funded warrants. The company details board structure, committee memberships, director compensation, and 2025 pay for named executives, including President and CEO David Kirn, M.D.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 5,247,151 shares of 4D Molecular Therapeutics, Inc., representing 10.3% of the common stock as disclosed. The filing states the Asset Managers exercise shared voting and dispositive power over these shares and disclaim rights to dividends or sale proceeds tied to the Managed Portfolios. The amendment is signed on 04/07/2026 and the cover lists 03/31/2026 in the header.
4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company’s Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer.
Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer’s prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare.
4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock. The option has an exercise price of $9.88 per share and expires on March 24, 2036.
The award vests over four years, with 1/48 of the shares vesting monthly starting on March 25, 2026, so long as he continues as a service provider. Following this grant, the filing shows 750,000 derivative securities (options) held directly by Kirn.
4D Molecular Therapeutics reported a stock option grant to Chief Legal Officer Scott Bizily. The award covers 217,000 options for common stock at an exercise price of $9.88 per share and expires on March 24, 2036.
The options vest in equal monthly installments over four years, with 1/48th of the underlying shares vesting on each monthly anniversary of March 25, 2026, so long as Bizily remains a service provider. This is a compensation-related equity grant, not an open-market share purchase or sale.